Login to Your Account



Aeterna Zentaris Prepares NDA for Growth Hormone Drug

By Catherine Shaffer


Wednesday, August 31, 2011
A growth hormone-stimulating drug by Aeterna Zentaris Inc., of Quebec City, achieved its endpoint as a diagnostic for adult growth hormone deficiency (AGHD) according to top-line results from a Phase III trial reported by the company Tuesday. The drug, AEZS-130 (Solorel), was given to a group of growth hormone-deficient and normal patients, and diagnosis based on response to the drug had sensitivity and specificity greater than 90 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription